STOCK TITAN

XWELL (XWEL) Stock Price, News & Analysis

XWEL NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
82 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+220.1% close of February 25, 2026
1-year change
-48.3% closing prices, November 18, 2025 to November 18, 2026
1-month change
-36.6% closing prices, October 16, 2026 to November 18, 2026

Company Description

XWELL, Inc. (Nasdaq: XWEL) is described in its public communications as a global wellness holding company focused on health, beauty, self-care, and biosecurity for people "on the go." According to recent press releases, the company positions itself as a leading provider of wellness solutions for people on the go, combining physical wellness locations with travel-focused services and pathogen surveillance programs.

Through its portfolio of brands – including XpresSpa, Naples Wax Center, XpresCheck, and HyperPointe – XWELL states that it aims to make self-care accessible and elevated in airports, major transportation hubs, and metropolitan areas. Company disclosures and news releases explain that XpresSpa and XWELL-branded locations operate in airports and other high-traffic environments, offering wellness treatments and products tailored to travelers and commuters. Naples Wax Center operates locations that focus on waxing and related skincare and cosmetic offerings. XpresCheck and HyperPointe support biosecurity and digital health infrastructure, including traveler-based pathogen surveillance and airport-based biosurveillance programs.

In its own descriptions, XWELL emphasizes that it is redefining the modern wellness experience by integrating health, beauty, and wellness services into everyday travel and community routines. The company highlights wellness centers in Florida and other metropolitan areas, as well as airport spas and wellness retail locations, as part of a broader effort to expand beyond airport-only operations. These locations feature services such as facials, massages, waxing, and other medical and wellness services, as described in XWELL’s Florida wellness center announcements, alongside wellness-focused retail and autonomous massage offerings in transportation hubs like New York City’s Pennsylvania Station.

XWELL also reports that it operates at the frontlines of biosecurity and biosurveillance through its XpresCheck brand and related digital capabilities. Company press releases explain that XWELL has supported the U.S. Centers for Disease Control and Prevention’s Traveler-based Genomic Surveillance (TGS) program in association with Ginkgo Bioworks, contributing to traveler-based pathogen surveillance at U.S. airports. The company states that this work enables early detection and monitoring of emerging infectious diseases at international points of entry. XWELL has also announced a global biosecurity strategy focused on traveler-based surveillance at international travel hubs and large-scale mass gathering events.

In addition, XWELL highlights a technology and data component through HyperPointe, which it describes as part of the operational and technological core of its biosurveillance and digital healthcare infrastructure. Company updates note that XWELL has integrated HyperPointe into existing operations to maintain digital platform and AI capabilities that support its wellness and biosecurity programs.

From a capital markets perspective, XWELL is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol XWEL, as indicated in its SEC filings and Nasdaq-related announcements. The company has disclosed that it has, at times, received notices from Nasdaq regarding minimum bid price compliance and has also reported regaining compliance with Nasdaq Listing Rule 5550(a)(2). These filings and notices show that XWELL remains subject to the listing standards and ongoing compliance requirements of Nasdaq.

Corporate governance and financing updates in XWELL’s SEC filings describe actions such as annual meetings of stockholders, advisory votes on executive compensation, auditor ratification, and proposals related to reverse stock splits and capital structure. The company has also reported entering into agreements involving Series G Convertible Preferred Stock, warrants, and senior secured convertible notes, along with related amendments and stockholder approval processes.

Overall, based on its own public statements, XWELL presents itself as a wellness-focused holding company that combines airport and off-airport wellness centers, travel-oriented spa and retail experiences, and biosecurity and biosurveillance programs supported by digital platforms. Its operations are centered on helping travelers, commuters, and local communities access health, beauty, and self-care services in high-traffic and everyday environments, while also working with public health stakeholders on pathogen surveillance at travel hubs.

Business segments and brands

Company materials and prior descriptions indicate that XWELL’s activities are organized around several brands and operating areas:

  • XpresSpa / XWELL airport and travel locations – Airport spas and wellness destinations that offer services and products for travelers, including massage, nail and skincare services, wellness-focused retail, and autonomous massage experiences. Recent news also describes XWELL-branded locations in major transportation hubs such as New York City’s Pennsylvania Station.
  • Naples Wax Center – A brand operating multiple locations with a focus on waxing services and related skincare and cosmetic products. Company descriptions highlight offerings spanning face and body waxing and a range of skincare and cosmetic items.
  • XpresCheck – A health and biosecurity platform that the company states helped power national COVID-19 testing and reporting and now serves as the operational and technological core of its airport-based biosurveillance initiatives, including the Traveler-based Genomic Surveillance program with the CDC and Ginkgo Bioworks.
  • HyperPointe – A digital and AI-enabled platform that XWELL associates with biosurveillance and digital healthcare infrastructure. The company notes that HyperPointe supports its science-driven wellness and biosecurity programs and has been integrated into broader operations.

Wellness and travel focus

Across press releases, XWELL consistently describes itself as a provider of wellness solutions for people on the go. It highlights airport spas, international partnerships that allow travelers to access autonomous massage and other wellness options, and off-airport wellness centers in Florida and other markets. These communications emphasize a strategy to diversify access points, extend wellness services beyond airport terminals, and engage with consumers where they live, work, and travel.

In partnership announcements, XWELL notes collaborations with organizations such as Priority Pass, which allows members to use lounge visit entitlements for autonomous massage sessions and other wellness options at XWELL and XpresSpa locations in North America and select international airports. The company also references partnerships in local markets, such as being named the official wellness spa of the Orlando Magic, to support its expansion into broader consumer wellness markets.

Biosecurity and pathogen surveillance

In addition to wellness centers and spa services, XWELL’s public statements emphasize a significant role in traveler-based pathogen surveillance. Through XpresCheck and in association with the CDC and Ginkgo Bioworks, the company reports supporting one of the largest traveler-based pathogen surveillance initiatives in the United States. XWELL notes that this work has enabled early detection and monitoring of emerging infectious diseases at international points of entry.

Recent announcements describe a global biosecurity strategy that builds on this U.S. foundation, with the company exploring expansion of traveler-based surveillance models to international travel hubs and large-scale mass gatherings. XWELL has also disclosed that it operates wellness and biosecurity programs across several major U.S. airports and works with public health stakeholders in major international travel corridors.

Capital structure and governance

SEC filings show that XWELL is a Delaware corporation with common stock and Series G Preferred Stock, and that it has undertaken various capital structure actions, including the issuance and amendment of preferred stock, warrants, and senior secured convertible notes. Proxy statements and 8-K filings detail proposals related to reverse stock splits, board classification, and the issuance of additional shares under Nasdaq listing rules, along with the outcomes of stockholder votes at annual meetings.

These filings also indicate that XWELL holds virtual annual meetings of stockholders, seeks advisory votes on executive compensation and its frequency, and discloses information about its independent registered public accounting firm. Notices from Nasdaq regarding minimum bid price compliance and subsequent regaining of compliance are part of the company’s disclosed listing history.

Stock Performance

$0.4655
-4.69%
-0.0229
Last updated: at
-48.3%
Performance 1 year

XWELL (XWEL) closed at $0.4655 on November 18, 2026. Over the past 12 months, the price has lost 48.3%.

See what a $1,000 investment in XWEL would be worth today

Average down calculator for XWEL

XWEL Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

XWELL generated $29.2M in revenue in FY2025, retaining a 25.7% gross margin, operating income reached -$15.7M (-53.6% operating margin), and net income was -$17.0M, reflecting a -58.2% net profit margin. Diluted earnings per share stood at -$5.08. The company generated -$8.7M in operating cash flow. The current ratio was 0.46, measuring current assets divided by current liabilities.

$29.2M
Revenue (FY2025)
-$17.0M
Net Income (FY2025)
-$8.7M
Operating Cash Flow

Upcoming Events

FEB
26
February 26, 2029 Financial

Warrants expiration

Placement warrants expire three years after issuance (assumes issuance at expected closing 2026-02-26)

XWELL has 1 upcoming scheduled event. The next event, "Warrants expiration", is scheduled for February 26, 2029 (in 830 days). It is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the XWEL stock price.

Short Interest History

Last 12 Months

Short interest in XWELL (XWEL) currently stands at 117.8 thousand shares, up 0.4% from the previous reporting period, representing 1.4% of the float. Since November 2025, short interest has increased by 64.7%.

Days to Cover History

Last 12 Months

Days to cover for XWELL (XWEL) currently stands at 2.2 days, up 14.1% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 118%. Across the settlements charted above, it has ranged from 1.0 to 7.2 days.

XWEL Company Profile & Sector Positioning

XWELL (XWEL) operates in the Diagnostics & Research industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing XWEL often look at related companies in the same sector, including ENDRA Life Sciences Inc. (NDRA), Advanced Biomed Inc. (ADVB), bioAffinity Technologies, Inc. (BIAF), MDxHealth SA (MDXH), and iSpecimen Inc. (ISPC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate XWEL's relative position within its industry.

Frequently Asked Questions

The current stock price of XWELL (XWEL) is $0.4655 as of November 18, 2026.

The market cap of XWELL (XWEL) is approximately $4.9M. Learn more about what market capitalization means .

The FY2025 revenue of XWELL (XWEL) is $29.2M, from its most recent completed fiscal year.

The FY2025 net income of XWELL (XWEL) is -$17.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of XWELL (XWEL) is -$5.08 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of XWELL (XWEL) is -$8.7M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of XWELL (XWEL) is -58.2% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of XWELL (XWEL) is -53.6% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of XWELL (XWEL) is 25.7% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of XWELL (XWEL), current assets divided by current liabilities, was 0.46 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of XWELL (XWEL) is $7.5M for FY2025, its most recent completed fiscal year.

The operating income of XWELL (XWEL) is -$15.7M for FY2025, its most recent completed fiscal year. Learn about operating income.

According to its public descriptions, XWELL, Inc. is a global wellness holding company focused on health, beauty, self-care, and biosecurity. It operates brands such as XpresSpa, Naples Wax Center, XpresCheck, and HyperPointe, combining airport and off-airport wellness centers with biosurveillance and digital health infrastructure.

XWELL states that its portfolio includes XpresSpa, Naples Wax Center, XpresCheck, and HyperPointe. These brands cover airport and travel wellness services, waxing and skincare offerings, and biosecurity and digital healthcare platforms.

Company announcements describe XWELL and XpresSpa locations in airports and transportation hubs, offering wellness services such as massage and other treatments, autonomous massage experiences, and wellness-focused retail. XWELL has also opened wellness locations in places like New York City’s Pennsylvania Station to serve busy commuters.

XWELL reports that, through XpresCheck and in association with Ginkgo Bioworks, it has supported the CDC’s Traveler-based Genomic Surveillance program. The company states that this initiative enables early detection and monitoring of emerging pathogens at international points of entry.

XWELL describes HyperPointe as part of its digital platform and AI capabilities that support biosurveillance and digital healthcare infrastructure. Company updates note that HyperPointe has been integrated into existing operations to help power science-driven wellness and biosecurity programs.

Public communications reference XWELL and XpresSpa locations in airports and metropolitan areas, including wellness centers in Florida and a location in New York City’s Pennsylvania Station. The company also notes operations across major U.S. airports and select international airports through partnerships.

XWELL’s SEC filings and Nasdaq notices indicate that its common stock is listed on The Nasdaq Capital Market under the ticker symbol XWEL.

Yes. SEC filings and press releases show that XWELL has received notices from Nasdaq regarding minimum bid price compliance under Listing Rule 5550(a)(2). The company has also disclosed regaining compliance after its share price met the required minimum bid price for a specified period.

XWELL’s SEC filings describe annual meetings of stockholders, advisory votes on executive compensation, auditor ratification, proposals for reverse stock splits and board classification, and transactions involving Series G Convertible Preferred Stock, warrants, and senior secured convertible notes.

In recent press releases, XWELL explains that it is expanding beyond airport terminals into broader consumer wellness markets by opening brick-and-mortar wellness centers in Florida and other metropolitan areas and by establishing wellness locations in high-traffic transportation hubs such as New York City’s Pennsylvania Station.